Insmed Q2 EPS $(1.78) Misses $(1.10) Estimate, Sales $77.23M Beat $70.25M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed reported Q2 losses of $(1.78) per share, missing the analyst consensus estimate of $(1.10) by 61.82%. This is a 122.5% decrease from the same period last year. However, the company's quarterly sales of $77.23 million beat the analyst consensus estimate of $70.25 million by 9.94%, marking an 18.41% increase from last year.
August 04, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Insmed's Q2 earnings per share missed estimates by 61.82%, but sales beat estimates by 9.94%.
Insmed's larger than expected loss per share could negatively impact the stock price. However, the better than expected sales might mitigate this impact to some extent.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100